Microbot Medical Positive Results of GLP Pivotal Pre-Clinical Study

Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announces the successful completion of its GLP pivotal pre-clinical study, done under the guidelines of FDA-required levels of planning, controlling, monitoring, and reporting, using a porcine model.

As previously announced on December 7, 2023, the study was conducted by three leading interventional radiologists that utilized the LIBERTY Endovascular Robotic Surgical System to perform a total of 96 robotic navigations. Target vessels with surrounding tissue were examined and evaluated microscopically after they were subjected to procedures using a range of commercially available intravascular catheterization devices controlled and manipulated via the LIBERTY Endovascular Robotic Surgical System.

https://www.globenewswire.com/news-release/2023/12/28/2801656/0/en/Microbot-Medical-Announced-Positive-Results-of-Its-GLP-Pivotal-Pre-Clinical-Study-Where-All-Study-Objectives-Were-Met.html